Literature DB >> 21945484

Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction?

Mette Skinbjerg1, David R Sibley, Jonathan A Javitch, Anissa Abi-Dargham.   

Abstract

Positron Emission Tomography (PET) has been used for more than three decades to image and quantify dopamine D2 receptors (D2R) in vivo with antagonist radioligands but in the recent years agonist radioligands have also been employed. In vitro competition studies have demonstrated that agonists bind to both a high and a low-affinity state of the D2Rs, of which the high affinity state reflects receptors that are coupled to G-proteins and the low-affinity state reflects receptors uncoupled from G-proteins. In contrast, antagonists bind with uniform affinity to the total pool of receptors. Results of these studies led to the proposal that D2Rs exist in high and low-affinity states for agonists in vivo and sparked the development and use of agonist radioligands for PET imaging with the primary purpose of measuring the proportion of receptors in the high-affinity (activating) state. Although several lines of research support the presence of high and low-affinity states of D2Rs and their detection by in vivo imaging paradigms, a growing body of controversial data has now called this into question. These include both in vivo and ex vivo studies of anesthesia effects, rodent models with increased proportions of high-affinity state D2Rs as well as the molecular evidence for stable receptor-G-protein complexes. In this commentary we review these data and discuss the evidence for the in vivo existence of D2Rs configured in high and low-affinity states and whether or not the high-affinity state of the D2R can, in fact, be imaged in vivo with agonist radioligands.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945484      PMCID: PMC3610415          DOI: 10.1016/j.bcp.2011.09.008

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  71 in total

1.  Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins.

Authors:  Nicolas Audet; Céline Galés; Elodie Archer-Lahlou; Marc Vallières; Peter W Schiller; Michel Bouvier; Graciela Pineyro
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

2.  High-affinity binding of agonists to beta-adrenergic receptors on intact cells.

Authors:  M L Toews; T K Harden; J P Perkins
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

3.  Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state.

Authors:  D R Sibley; L C Mahan; I Creese
Journal:  Mol Pharmacol       Date:  1983-03       Impact factor: 4.436

4.  Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists.

Authors:  A De Lean; B F Kilpatrick; M G Caron
Journal:  Mol Pharmacol       Date:  1982-09       Impact factor: 4.436

5.  Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.

Authors:  Rajesh Narendran; Mark Slifstein; Olivier Guillin; Yuying Hwang; Dah-Ren Hwang; Erica Scher; Stephanie Reeder; Eugenii Rabiner; Marc Laruelle
Journal:  Synapse       Date:  2006-12-01       Impact factor: 2.562

6.  Syntheses and in vitro evaluation of fluorinated naphthoxazines as dopamine D2/D3 receptor agonists: radiosynthesis, ex vivo biodistribution and autoradiography of [(18)F]F-PHNO.

Authors:  Neil Vasdev; Philip Seeman; Armando Garcia; Winston T Stableford; José N Nobrega; Sylvain Houle; Alan A Wilson
Journal:  Nucl Med Biol       Date:  2007-01-17       Impact factor: 2.408

7.  Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo.

Authors:  Patrick N McCormick; Shitij Kapur; Philip Seeman; Alan A Wilson
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

8.  Abundance and stability of complexes containing inactive G protein-coupled receptors and G proteins.

Authors:  Kou Qin; Pooja R Sethi; Nevin A Lambert
Journal:  FASEB J       Date:  2008-04-23       Impact factor: 5.191

9.  Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA.

Authors:  Nicholas Seneca; Sami S Zoghbi; Mette Skinbjerg; Jeih-San Liow; Jinsoo Hong; David R Sibley; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  Synapse       Date:  2008-10       Impact factor: 2.562

10.  Dopamine D2(High) receptors on intact cells.

Authors:  Philip Seeman
Journal:  Synapse       Date:  2008-04       Impact factor: 2.562

View more
  33 in total

1.  Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.

Authors:  David Matuskey; Patrick Worhunksy; Elizabeth Correa; Brian Pittman; Jean-Dominique Gallezot; Nabeel Nabulsi; Jim Ropchan; Venkatesh Sreeram; Rohit Gudepu; Edward Gaiser; Kelly Cosgrove; Yu-Shin Ding; Marc N Potenza; Yiyun Huang; Robert T Malison; Richard E Carson
Journal:  Neuroimage       Date:  2016-02-11       Impact factor: 6.556

2.  Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users.

Authors:  Isabelle Boileau; Doris Payer; Pablo M Rusjan; Sylvain Houle; Junchao Tong; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2016-06-29       Impact factor: 7.853

Review 3.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

Review 4.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 5.  Advances in simultaneous PET/MR for imaging neuroreceptor function.

Authors:  Christin Y Sander; Hanne D Hansen; Hsiao-Ying Wey
Journal:  J Cereb Blood Flow Metab       Date:  2020-03-13       Impact factor: 6.200

6.  Convenient synthesis of 18F-radiolabeled R-(-)-N-n-propyl-2-(3-fluoropropanoxy-11-hydroxynoraporphine.

Authors:  Anna W Sromek; Shaohui Zhang; Vamsidhar Akurathi; Alan B Packard; Wei Li; David Alagille; Thomas J Morley; Ronald Baldwin; Gilles Tamagnan; John L Neumeyer
Journal:  J Labelled Comp Radiopharm       Date:  2014-11-17       Impact factor: 1.921

7.  Detection of phasic dopamine by D1 and D2 striatal medium spiny neurons.

Authors:  Cedric Yapo; Anu G Nair; Lorna Clement; Liliana R Castro; Jeanette Hellgren Kotaleski; Pierre Vincent
Journal:  J Physiol       Date:  2017-09-02       Impact factor: 5.182

8.  Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain.

Authors:  Vasko Kramer; Agnete Dyssegaard; Jonathan Flores; Cristian Soza-Ried; Frank Rösch; Gitte Moos Knudsen; Horacio Amaral; Matthias M Herth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-12       Impact factor: 9.236

Review 9.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

Review 10.  The role of D2-autoreceptors in regulating dopamine neuron activity and transmission.

Authors:  C P Ford
Journal:  Neuroscience       Date:  2014-01-23       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.